Sebastian Szmit: Advances in Managing Cancer-Associated Thromboembolism
OncoDaily shared on LinkedIn:
”Dr. Sebastian Szmit Highlights Advances in Managing Cancer-Associated Thromboembolism at GCOS 2025
Dr. Sebastian Szmit, from the Institute of Hematology and Transfusion Medicine and the Center of Postgraduate Medical Education in Warsaw, delivered an engaging talk on cancer-associated thromboembolism. He discussed premature mortality linked to VTE in cancer patients and reviewed ESC guideline–based anticoagulation options, comparing DOACs (apixaban, edoxaban, rivaroxaban) with low-molecular-weight heparin (LMWH). He emphasized that while DOACs are effective, LMWH remains preferred in gastrointestinal cancers due to higher bleeding risks.
Dr. Szmit also presented findings from the APICAT study, which showed that a reduced dose of apixaban can maintain efficacy while lowering bleeding risk during extended anticoagulation. He highlighted challenges such as drug interactions, thrombocytopenia, and the need for improved primary prophylaxis strategies tailored to cancer therapy.”
Stay informed with Hemostasis Today.
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice
-
Jul 2, 2026, 21:49Lee Peter Bee: The Plastic in Your Blood Is Sabotaging Your Stem Cells
-
Jul 2, 2026, 21:49Atef Ahmed: The Lethal Triad and Damage Control Philosophy
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT